Sara Pellegrino | Senior Vice President, Investor Relations and Corporate Communications |
Fred Vogt | Interim President and Chief Executive Officer |
Igor Bilinsky | Chief Operating Officer |
Jim Ziegler | Executive Vice President, Commercial |
Friedrich Finckenstein | Chief Medical Officer |
Jean-Marc Bellemin | Chief Financial Officer |
Raj Puri | Executive Vice President, Regulatory Strategy and Translational Medicine |
Peter Lawson | Barclays |
Mark Breidenbach | Oppenheimer |
Ben Burnett | Stifel |
Reni Benjamin | JMP Securities |
Mara Goldstein | Mizuho Group |
Kelsey Goodwin | Guggenheim Partners |
Karina Rabayeva | Truist |
Welcome to the Iovance Biotherapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. My name is Gigi and I will be your operator for today’s call. [Operator Instructions] Please note that this conference is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin.